← Back to Screener
Silexion Therapeutics Corp Warrant (SLXNW)
Price$0.03
Favorite Metrics
Price vs S&P 500 (26W)-5.73%
Price vs S&P 500 (4W)-21.71%
All Metrics
Price vs S&P 500 (YTD)4.95%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.07M
52-Week High$0.15
26-Week Price Return-3.57%
13-Week Price Return-18.92%
3-Month Return Std Dev345.76%
Year-to-Date Return3.85%
5-Day Price Return92.86%
Month-to-Date Return-19.16%
Price vs S&P 500 (13W)-18.42%
Beta-0.64x
52-Week Low$0.01
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLXNWSilexion Therapeutics Corp Warrant | — | — | — | — | $0.03 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers. Its lead candidate, SIL204, is a locally administered RNA interference therapy targeting locally advanced pancreatic cancer patients with specific KRAS mutations (G12D/G12V), used in combination with standard chemotherapy. The therapy addresses non-resectable tumors that cannot be surgically removed, representing a significant unmet medical need.